Chronic kidney disease is often characterized by the presence of sympathetic hyperactivity. The aim of this brief review is to summarize available knowledge on the pathogenesis of sympathetic hyperactivity and to discuss its clinical relevance, the consequences of this knowledge for the choice of treatment, and the yet unresolved issues.
JolesJAKoomansHA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension2004; 43:699–706.
3.
KoomansHABlankestijnPJJolesJA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol2004; 15:524–37.
4.
NeumannJLigtenbergGKleinIIKoomansHABlankestijnPJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int2004; 65:1568–76.
5.
BlankestijnPJLigtenbergG.Volume-independent mechanisms of hypertension in hemodialysis patients: clinical implications. Semin Dial2004; 17:265–9.
6.
AugustyniakRATuncelMZhangWTotoRDVictorRG. Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens2002; 20:3–9.
7.
CampeseVMMitraNSandeeD.Hypertension in renal parenchymal disease: why is it so resistant to treatment?Kidney Int2006; 69:967–73.
8.
KotankoP.Cause and consequences of sympathetic hyperactivity in chronic kidney disease. Blood Purif2006; 24:95–9.
9.
GrassiGEslerM.How to assess sympathetic activity in humans. J Hypertens1999; 17:719–34.
10.
ConverseRLJrJacobsenTNTotoRDJostCMCosentinoFFouad–TaraziF. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med1992; 327: 1912–18.
11.
HausbergMKoschMHarmelinkPBarenbrockMHohageHKistersK. Sympathetic nerve activity in end-stage renal disease. Circulation2002; 106:1974–9.
12.
KleinIHLigtenbergGNeumannJOeyPLKoomansHABlankestijnPJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol2003; 14:3239–44.
13.
KleinIHLigtenbergGOeyPLKoomansHABlankestijnPJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol2001; 12:2427–33.
14.
KleinIHLigtenbergGOeyPLKoomansHABlankestijnPJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol2003; 14:425–30.
15.
LigtenbergGBlankestijnPJOeyPLKleinIHDijkhorst-OeiLTBoomsmaF. Reduction of sympathetic hyper-activity by enalapril in patients with chronic renal failure. N Engl J Med1999; 340:1321–8.
16.
NeumannJLigtenbergGOeyLKoomansHABlankestijnPJ. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol2004; 15:2902–7.
MiyajimaEYamadaYYoshidaYMatsukawaTShionoiriHTochikuboO. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension1991; 17:1057–62.
19.
KielsteinJTImpraimBSimmelS.Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation2004; 109:172–7.
20.
ZoccaliCBode–BogerSMallamaciFBenedettoFTripepiGMalatinoL. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end- stage renal disease: a prospective study. Lancet2001; 358: 2113–17.
21.
ZoccaliCMallamaciFMaasRBenedettoFATripepiGMalatinoLS. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int2002; 62:339–45.
22.
MallamaciFZoccaliCMessineoLParlongoSPostorinoM.The influence of volume depletion and central hypovolemia on the plasma concentration of parathyroid hormone in dialysis patients. J Am Soc Nephrol1997; 8:1574–8.
23.
HanlyPJPierratosA.Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med2001; 344:102–7.
GreenwoodJPScottEMStokerJBMaryDA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol2001; 38:1711–17.
26.
KelmMSchaferSMingersSHeydthausenMVogtMMotzW. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens1996; 14:1357–64.
27.
SchlaichMPKayeDMLambertESommervilleMSocratousFEslerMD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation2003; 108:560–5.
28.
ZoccaliCMallamaciFTripepiGParlongoSCutrupiSBenedettoFA. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension2002; 40:41–6.
29.
ZoccaliCBenedettoFAMallamaciFTripepiGGiaconeGCataliottiA. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol2001; 12:2768–74.
30.
ManciaGGrassiGGiannattasioCSeravalleG.Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension1999; 34:724–8.
31.
ZoccaliCMallamaciFParlongoSCutrupiSBenedettoFATripepiG. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation2002; 105:1354–9.
32.
AmannKKochAHofstetterJGrossMLHaasCOrthSR. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int2001; 60:1309–23.
33.
AmannKRumpLCSimonavicieneAOberhauserVWesselsSOrthSR. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol2000; 11:1469–78.
34.
StrojekKGrzeszczakWGorskaJLeschingerMIRitzE.Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy?J Am Soc Nephrol2001; 12:602–5.
35.
CiceGFerraraLD'AndreaAD'IsaSDi BenedettoACittadiniA. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol2003; 41:1438–44.
36.
CiceGDiBenedettoAD'IsaSD'AndreaADeGregorioPCalabroR.Effect of telmisartan added to ACE inhibitors in reducing morbidity and mortality in hemodialysis patients with chronic heart failure (Abstract). J Hypertens2006; 24(Suppl 4):S21.
37.
ChanCTHarveyPJPictonPPierratosAMillerJAFlorasJS. Short-term blood pressure, noradrenergic and vascular effects of nocturnal home hemodialysis. Hypertension2003; 42:925–31.
38.
ZilchOVosPFOeyPL. Sympathetic hyperactivity in hemodialysis patients is reduced by short daily hemodialysis. J Hypertens2007; [In press].
39.
KielsteinJTBode–BogerSMFrolichJCHallerHBogerRH. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int2001; 59(Suppl 78):S9–13.
40.
ZoccaliC.Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int2006; 70:26–33.
41.
NishiyamaASethDMNavarLG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension2002; 39:129–34.
42.
SongJHChaSHHongSBKimDH. Dual blockade of the renin–angiotensin system with angiotensin converting-enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J Hypertens2006; 24(Suppl 1):S101–6.
43.
WolfGRitzE.Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int2005; 67:799–812.
44.
NakaoNYoshimuraAMoritaHTakadaMKayanoTIdeuraT.Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet2003; 361:117–24.
45.
PenneELNeumannJKleinIHKoomansHABlankestijnPJ. Relation between sympathetic hyperactivity and clinical outcome in chronic kidney disease patients (Abstract). J Hypertens2006; 24(Suppl 4):S294.
46.
SinskiMLewandowskiJBidiukJAbramczykPGaciongZ.Atorvastatin reduces sympathetic activity in patients with essential hypertension and hypercholesteremia (Abstract). J Hypertens2006; 24(Suppl 4):S381.
